|
|
|
Volumn 6, Issue 4, 2004, Pages 451-457
|
|
Technology evaluation: ABT-510, Abbott
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
15 DEOXY DELTA12,14 PROSTAGLANDIN J2;
ABT 526;
ANGIOGENESIS INHIBITOR;
ANGIOSTATIN;
CARBOPLATIN;
ENDOSTATIN;
FUMAGILLOL CHLOROACETYLCARBAMATE;
N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE;
PACLITAXEL;
THALIDOMIDE;
THROMBOSPONDIN 1;
UNCLASSIFIED DRUG;
ANGIOGENESIS;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
ASTHENIA;
BLADDER CANCER;
BLEEDING;
BLOOD TOXICITY;
BONE PAIN;
BREAST CANCER;
CANCER INHIBITION;
CHILL;
CLINICAL TRIAL;
COLORECTAL CANCER;
CONSTIPATION;
DEVELOPMENTAL DISORDER;
DISEASE MODEL;
DOSE RESPONSE;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG HYPERSENSITIVITY;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG POTENTIATION;
DRUG SYNTHESIS;
DRUG TOLERABILITY;
DYSPNEA;
HEADACHE;
HUMAN;
IN VITRO STUDY;
IN VIVO STUDY;
INJECTION SITE;
KIDNEY CARCINOMA;
LIMB DEVELOPMENT;
LUNG CANCER;
LUNG METASTASIS;
LYMPHOMA;
MELANOMA;
NAUSEA;
NONHUMAN;
SARCOMA;
SOLID TUMOR;
STRUCTURE ACTIVITY RELATION;
TOXICITY TESTING;
TRANSIENT ISCHEMIC ATTACK;
TREMOR;
TUMOR VASCULARIZATION;
VOMITING;
AMINO ACID SEQUENCE;
ANGIOGENESIS INHIBITORS;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE II;
HUMANS;
MICE;
OLIGOPEPTIDES;
THROMBOSPONDIN 1;
|
|
EID: 4444335653
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (30)
|
|
References (0)
|
